Clinical trial
A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients
NCT03715023 is registered in ClinicalTrials.gov with Pulmocide Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients
- Lead sponsor
- Pulmocide Ltd
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 5, 2018
- Completion date
- May 1, 2019
- Enrollment
- 5 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.